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Abstract
Background: Cardiovascular risk management (CVRM) is notoriously difficult because of multi-morbidity and the
different phenotypes and severities of cardiovascular disease. Computerized decision support systems (CDSS) enable
the clinician to integrate the latest scientific evidence and patient information into tailored strategies. The effect on
cardiovascular risk factor management is yet to be confirmed.
Methods: We performed a systematic review and meta-analysis evaluating the effects of CDSS on CVRM, defined as
the change in absolute values and attainment of treatment goals of systolic blood pressure (SBP), low density
lipoprotein cholesterol (LDL-c) and HbA1c. Also, CDSS characteristics related to more effective CVRM were identified.
Eligible articles were methodologically appraised using the Cochrane risk of bias tool. We calculated mean differences,
relative risks, and if appropriate (I2 < 70%), pooled the results using a random-effects model.
Results: Of the 14,335 studies identified, 22 were included. Four studies reported on SBP, 3 on LDL-c, 10 on CVRM in
patients with type II diabetes and 5 on guideline adherence. The CDSSs varied considerably in technical performance
and content. Heterogeneity of results was such that quantitative pooling was often not appropriate. Among CVRM
patients, the results tended towards a beneficial effect of CDSS, but only LDL-c target attainment in diabetes patients
reached statistical significance. Prompting, integration into the electronical health record, patient empowerment, and
medication support were related to more effective CVRM.
Conclusion: We did not find a clear clinical benefit from CDSS in cardiovascular risk factor levels and target attainment.
Some features of CDSS seem more promising than others. However, the variability in CDSS characteristics and
heterogeneity of the results – emphasizing the immaturity of this research area - limit stronger conclusions.
Clinical relevance of CDSS in CVRM might additionally be sought in the improvement of shared decision making and
patient empowerment.
Keywords: CDSS, Computerized decision support, Cardiovascular risk management
Background
The fast paced nature of medical science and practice
challenge physicians to keep practicing concurrent to
guidelines and the latest evidence. Some state that health
care decision making has never been more complex
because of multi morbidity and different severities of
disease clustered in one individual [1]. Cardiovascular risk
management (CVRM) in high-risk patients asks for a
comprehensive approach and a lifelong effort of patients
that affects lifestyle and dictates adherence to medical
treatment of risk factors. CVRM is complex, because it
involves a large number of risk factors that may change
over time. CVRM guidelines provide support and advo-
cate the use of risk prediction algorithms for the identi-
fication of patients at risk for (recurrent) cardiovascular
events [2]. Treatment decisions, such as starting or inten-
sifying lipid blood pressure lowering treatment are based
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on estimated absolute cardiovascular risk in individual
patients and their absolute levels of risk factors. Yet,
there seems to be a gap between guideline recommen-
dations and daily clinical practice [3]. Adherence to guide-
lines varies between medical disciplines and between
treating physicians, even for similar patients [3]. Com-
pleteness of risk factor assessment, pharmacological and
non-pharmacological treatment initiation and long term
uptake of treatment in patients with a cardiovascular
condition can be further optimized, which potentially
leads to reduction in to preventable cardiovascular
morbidity and mortality [4, 5].
Computerized decision support systems (CDSS) are
digital information systems that typically show a summary
of patient data in an app, on a webpage, or within the elec-
tronic health record (EHR). In CVRM, CDSS can be used
for reminders for assessment of risk factor levels, compre-
hensive presentation and evaluation of risk factor levels
and cardiovascular risk estimates and for recommendation
of evidence-based treatment modalities. This way, patient
data and scientific evidence are incorporated into tailored
strategies in daily practice [6]. CDSS have the potential to
improve shared decision making, treatment adherence and
eventually health outcome, without additional utilization of
health-care resources [7].
Multiple apps and decision support systems have been
and are being developed: over the last years, at least 16
systematic and 2 narrative reviews on the effectiveness of
CDSS on practitioner performance and patient outcomes
have been published [8–25]. But due to the large variation
in CDSS functionalities – drug alerts, laboratory test
ordering, treatment advice – clinical applications, and
patient populations these reviews are restricted in terms
of generalizability and applicability. Cardiovascular disease
prevention is a multidisciplinary process in a population
characterized by multimorbidity and multiple diseases of
different severities. Preferably, a CDSS focused on CVRM
should fit all these patients. Recently, Njie et al. reported a
systematic review on CDSS in cardiovascular risk manage-
ment, focusing on improvement in guideline adherence by
physicians [26]. Complete assessment of vascular risk
factors and guideline-adherent clinical testing increased)
[26]. It would be even more clinically relevant to know
whether use of CDSS would improve cardiovascular risk
factor levels and ultimately reduce cardiovascular event
rates. This is yet to be investigated.
This systematic review of randomized clinical trials eval-
uates the effects of CDSS on CVRM and aims to identify
CDSS characteristics that are related to effective CVRM.
Methods
This review was performed in accordance with the Pre-
ferred Reporting Items for Systematic Reviews (PRISMA)
guidelines [27].
Outcomes of interest
The primary focus of the systematic review was on abso-
lute difference in and target attainment of blood pres-
sure, LDL-c and HbA1c. The secondary focus was on
the evidence based medicine practice performance of the
user, defined as actions compliant to the guidelines
applied in the specific studies. Lastly we investigated
whether the technical embedding, the measurements
provided, the level of evidence provided, the level of
therapy advice provided and prompting were related to
the likelihood of having positive, beneficial results.
Study eligibility
Randomized controlled trials (RCT’s) and cluster RCT’s
using CDSS as an intervention on CVRM were included.
As parameters for CVRM the established, objectively
measurable and pharmacological treatable risk factors
were used: elevated blood pressure, impaired glycemic
control and dyslipidemia. Although relevant in CVRM,
effects on lifestyle factors such as smoking and physical
inactivity were outside the scope of this review.
Studies were included if the CDSS was used for a
patient specific advice given to the physician or about to
make a treatment decision for the individual patient (not
the group-effect). Studies on medical training or primary
users other than physicians were excluded. Assessments
of diagnostic or prognostic CDSS tools compared with
routine care were excluded. Advice on prescription of
medicine supported by CDSS was included, but drug
prescribing error alarm systems were not. Clinical sup-
port using out-of-date systems (fax, paper flowcharts
etc.) or trials focusing on implementation of an EHR
were excluded.
Search strategy
A systematic literature search was conducted in PubMed,
Embase and Cochrane Library for publications up to
March 20th 2018. A combination synonyms of “compu-
terized decision support systems” AND (“system perform-
ance” OR “hypertension” OR “dyslipidemia” OR
“diabetes”) AND “randomized controlled trial” and syno-
nyms was used. The detailed search strategy is in
Additional file 1.
Data collection and assessment of methodological quality
A data collection form was designed prior to screening
of the retrieved articles. KG subtracted the data from the
retrieved articles. Uncertainties were resolved by dis-
cussion with an objective expert (Prof. Dr. R. Scholten).
Additional quality assessment was performed using the
Cochrane Collaboration’s tool to assess the risk of bias
[28]. Blinding of participants and physicians was not
possible due to the nature of the intervention. Therefore
we excluded this criterion from the appraisal. All studies
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were scored on the randomization process, blinding of
outcome assessment, attrition bias, reporting bias and
other potential sources of bias. Additionally, cluster
RCT’S were assessed on recruitment bias, baseline im-
balance, loss of clusters, adjustments for clustering in
the analysis and comparability with individually rando-
mized trials. Items were scored low risk of bias, unknown
risk of bias or high risk of bias. Studies with more than
two items at ‘a high risk of bias’ were excluded from
further analyses.
Data processing and additional analyses were per-
formed in RevMan [29]. For continuous outcomes, we
calculated the mean differences (MDs) with 95% confi-
dence intervals (CI’s) between CDSS and usual care at
follow up. For dichotomous outcomes, we calculated the
relative risks with 95% CI’s between CDSS and usual
care at follow up. If standard deviations were missing,
we calculated them using reported CIs, standard errors,
t and/or p values, according to the principles provided
in the Cochrane handbook [30]. We assessed heteroge-
neity using the I2 [31]. Results were considered too
heterogeneous for reliable pooling if the I2 was > 70%
[32]. Where appropriate, results were pooled using a
random-effects model.
Results
The systematic literature search (Additional file 1)
yielded 14,335 unique articles. Figure 1 shows the num-
ber of articles that were retrieved from the searches,
were reviewed and were included in the analysis. After
selection based on title and abstract, 53 articles were
considered potentially eligible for answering the research
question. Full text screening followed. Three studies
were excluded because of the study design: one study
performed a retrospective cross sectional study [33], two
studies performed a before and after study [34, 35]. Dorr
et al. did not focus solely on CVRM interventions [36]
and was excluded. Four studies featured interventions
focusing on influencing patient behaviour [37], learning
strategies [38], data search queries [39] or prediction
models [40] that were non-compatible with our inter-
vention of choice, and were excluded. Three articles fo-
cused on patient and physician satisfaction and/or CDSS
uptake rather than measurable clinical outcomes and
were excluded [41–43]. Ten studies did not answer our
research question [44–52]. Three studies featured an
out-of-date system, three focused on the implementation
of an EHR [53–59]. Lipton et al. investigated glucose
control at the intensive care unit, which was considered
a too different population [60]. Also a study on a con-
tinuous monitoring system was excluded from further
assessments [61]. That left us with 25 studies that were
critically appraised.
Critical appraisal
Randomization process was not sufficiently reported by
two studies [62, 63] (Additional file 2. Critical appraisal
table). Two studies reported considerable (up to > 20%)
loss to follow up [62, 64]. Furthermore insufficient infor-
mation was provided on the prevention of (selection and
detection) bias by Saenz et al. [63] That left us with 17
articles on risk factor changes (Table 1) proceeded to
data analysis and 5 articles providing evidence on guide-
line adherence.
CVRM on elevated blood pressure
A total of 4 studies investigated blood pressure and
blood pressure target attainment in CVRM patients
(Table 1), of which 3 looked at mean blood pressure
(Fig. 2.1) [65, 67, 68] and 3 at target attainment (Fig. 2.2)
[65, 66, 68] . The studies were performed in primary
Fig. 1 Flowchart
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care practices, mostly with a follow up of 12 months.
The CDSS was integrated in the electronical health
record in 3 studies [65–67]. All CDSS provided a risk
factor overview, only 2 a cardiovascular risk score
[65, 67]. Prompting occurred in 3 studies [65, 66, 68].
In the studies on absolute change in mean blood pres-
sure, 1594 patients received CDSS care and 1237 usual
care. The mean blood pressure decreased more in those
with CDSS care compared to usual care in 2 out of 3
studies. The overall pooled mean difference in systolic
pressure was − 1.49 mmHg (95%CI -5.861; 2.63), but
heterogeneity of results (I2 = 67%) is only just below the
maximum I2 for a reliable meta-analysis [65, 66, 68].
In the studies on target attainment, 1901 patients
received CDSS care and 2078 usual care. The number of
patients reaching their blood pressure goal was higher
with CDSS care than with usual care (pooled risk ratio
[RR] 1.22 (95%CI 0.85; 1.74), but the heterogeneity of
results (I2 = 95%) was too large to perform a reliable
meta-analysis [65, 67, 68].
A total of 7 studies investigated blood pressure and
blood pressure target attainment in patients with type II
diabetes (Table 1), of which 6 studies investigated mean
blood pressure [72, 73, 76, 80, 81] and 5 investigated
target attainment [72, 73, 77, 80, 81]. The studies were
performed in primary care practices, mostly with a
follow up was 12months. The CDSS was integrated in
the electronical health record in 4 studies. All CDSS
provided a risk factor overview, none a cardiovascular
risk score. Prompting occurred in 1 study [72].
The overall pooled mean difference in systolic pressure
and difference in number of patients reaching their
blood pressure goal was comparable to the CVRM
population: studies were relatively more positive towards
CDSS care, but the heterogeneity of results (I2 > 83%)
was too large to perform a reliable meta-analysis.
CVRM on dyslipidemia
A total of 3 studies investigated lipid control in CVRM pa-
tients (Table 1), of which 1 study investigated mean LDL-c
[71] and 2 investigated LDL-c target attainment [69, 70].
The studies were conducted in primary care practices with
a follow up of 12months [69–71].The CDSS was built
within the electronical health record in two studies [70, 71].
Fig. 2 2.1 Absolute change of mean systolic blood pressure
(mmHg) at follow up in CDSS and usual care. 2.2 Prevalence of
blood pressure target attainment at follow up in CDSS and usual
care. 2.3 Absolute change of LDL-c change (mmol/L) at follow up in
CDSS and usual care. 2.4 Prevalence of LDL-c target attainment at
follow up in CDSS and usual care. 2.5 Absolute change in mean
HbA1c in patients with type II diabetes (mmol/mol). 2.6 Prevalence
of HbA1c target attainment in patients with type II diabetes at
follow up in CDSS and usual care
Groenhof et al. BMC Medical Informatics and Decision Making          (2019) 19:108 Page 5 of 12
Eaton et al. used a PDA based system and integrated pa-
tient support into the program [69]. All CDSS provided a
risk factor overview, target support and medication sup-
port. None of the CDSSs’ featured a cardiovascular risk
score. Prompting occurred in two studies [70, 71].
Only one study reported on change in mean LDL-c
(slightly lower after CDSS (− 0.48 (0.08) mmol/L) than after
usual care (− 0.41 (0.09) mmol/L; Fig. 2.3) [71]. The studies
on target attainment showed contradictory results. On
average, there was no difference between CDSS and usual
care groups (RR 1.01 (95%CI 0.89; 1.14), I2 98%) [69, 70].
A total of 6 studies investigated lipid control in patients
with type II diabetes (Table 1), of which 5 studies investi-
gated mean LDL-c [73, 76, 78, 80, 81] and 5 investigated
LDL-c target attainment [72, 73, 77, 78, 80, 81].
The 6 studies targeting cholesterol performed in
patients with type II diabetes (7858 CDSS, 7586 usual
care) showed widely variable results for mean LDL-c
change (I2 79%, Fig. 2.3.1). A borderline statistically signifi-
cant improvement of attained LDL targets was found in
CDSS care compared to usual care (pooled RR 1.10(95%
CI 1.02; 1.09), I2 88%; Fig. 2.4.1).
CVRM on glycemic control in diabetics
A total of 10 studies investigated glycemic control in
patients with type II diabetes (Table 1), of which 9 studies
investigated mean HbA1c [72–76, 78–81] and 7 investi-
gated HbA1c target attainment [72, 73, 75, 77, 78, 80, 81].
Cleveringa et al. was the only study with a non-inferiority
design [73]. Most studies were conducted in primary care
practices and the follow up ranged from 6months to 2
years. As far as described, three studies were EHR based
[75, 77, 80], two web-applications [72, 76], one personal
digital assistant (PDA)/tablet [79], 1 CD-rom [74] and one
system using the EHR to extract data but using fax for
promoting [78]. All studies provided a risk factor overview
but none a cardiovascular risk score. Furthermore, two in-
cluded patient motivating techniques into the intervention
[75, 76]. Additionally, four studies organized a guideline
instruction session [72, 73, 79, 81].
In the studies on absolute change in mean HbA1c, 8483
patients received CDSS care and 8181 usual care. The
mean HbA1c seems to decrease more after CDSS care
than after usual care (MD -0.07% (95% CI -0.25;-0.11%), I2
82%; Fig. 2.5) [72–76, 78–81]. Similar prevalence HbA1c
target attainment (CDSS n = 7774, usual care n = 7531)
was found in care supported by CDSS and usual care (RR
1.05 (95%CI 0.96; 1.16); Fig. 2.6) [72, 73, 75, 77, 78, 80, 81].
There was insufficient homogeneity to reliably conduct
pooled analysis (I2 87%).
Usual care characteristics
Detailed description of usual care was lacking in 20
of the 24 reports. Roumie et al. sent all participants
an e-mail message that explained the planned inter-
vention and provided physician education in all groups
[68]. Similarly, a poster with a CVRM flowchart including
which risk factors to assess, classification of risk instruc-
tions and advice for lifestyle interventions was provided to
the usual care group in another study [65]. A patient acti-
vation tool was provided via a PDA with smoking cessa-
tion, weight loss, healthy diets, exercise and lipid lowering
medication adherence materials and web access to calcu-
late the heart-age in the study of Eaton et al. [69]. Grant et
al. provided their controls with a questionnaire on family
history and health maintenance journals [75].
CDSS characteristics
Apart from the technical performance of CDSS, design
and usability are important drivers behind the success of
the systems. The interaction design can influence error
through the length and proximity of selection items,
bullet points and similar item descriptions [82]. A study
on design characteristics showed that information
should be displayed all at once and at one glance [83].
The CDSS characteristics of the studies included in
this analysis are listed in Table 2. The cardiovascular
risk score was only provided by two of the studies on
blood pressure care, not in patients with type II dia-
betes [65, 67]. Advice on specific medication (name
and dose) was not unanimously associated with improve-
ment of the health outcomes [65, 66, 69, 70, 71, 75, 77, 79,
80]. Prompting of measurements and treatment strategies
were associated with positive CDSS results in five out of
seven studies [66, 68, 70–72, 78, 84]. Studies using
prompting that were not associated with positive results
used a web-link (not EHR) based [68] and fax reminders
[78]. Almost all studies in patients with type II diabetes
include patient activation in the CDSS intervention.
The lack of insight into the automated computation
and the source of information decreased user satisfaction
[85, 86]. CDSS built in within the EHR were superior to
usual care in seven out of nine studies. Non-EHR based
systems CDSS were superior to usual care in three out of
eight studies.
Guideline adherence
Five RCT’s reported on general improvement of ad-
herence to guidelines in patients with an indication
for CVRM, with and without diabetes and/or a history of
a cardiovascular event (Table 3) [87–91].
The CARDSS (cardiac rehabilitation decision support
system) was implemented in 21 centers (including 2878
patients), focusing on exercise, education, relaxation and
lifestyle change after a cardiac event. CDSS increased con-
cordance with guideline recommended interventions by
3.5% (95%CI 0.1; 5.2%). Furthermore, CDSS significantly
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reduced both overtreatment (25.7% (95%CI 4.3; 54.1%))
and under treatment (42.8% (95%CI 1.1; 68.0%)) [87].
The COMPETE III (Computerization of Medical Prac-
tices for the Enhancement of Therapeutic Effectiveness)
study assessed electronic vascular risk decision support
in patients with increased risk or a history of a car-
diovascular disease. The CDSS improved a composite
process outcome with 4.70 points on a 27 point scale
((95%CI 3.63; 5.71) p < 0.001). The CDSS group reported
a higher improvement of the continuum of care (odds
ratio (OR) 4.18 (95%CI 3.04; 5.76), p < 0.001) and
their ability to improve their health (OR 3.07 (95%CI
2.37; 3.99) p < 0.01) [88]. In patients with diabetes
without and with a history of acute myocardial infarc-
tion (n = 3956) and stroke (n = 2158), more antiplatelet
drugs (+ 2.7% vs + 0.15%; p < 0.001) and lipid lowering
drugs (+ 4.2% vs. + 2.8%, p = 0.001) were prescribed in the
CDSS group [89]. Another study amongst patients with
diabetes (n = 4549) and coronary artery disease (CAD,
n = 2199) also showed an improvement of diabetes care
(OR 1.30 95%CI 1.01; 1.67) and coronary heart disease risk
management (OR 1.25 (95%CI 1.01, 1.55)) amongst the
CDSS patients [91]. Lastly, in a study in > 7000 patients in
primary care showed an increase in the number of defi-
ciencies addressed amongst patients with diabetes or CAD
(CDSS 11.4% vs. normal care 10.1% (OR 1.14 (95%CI 1.02,
1.28), p = 0.01) [90].
Discussion
A systematic review and meta-analysis was conducted to
provide insight into the effects of computerized decision
support systems (CDSS) on cardiovascular risk factor
levels and identify characteristics of CDSS related to im-
proved care. A considerable number of CDSS for
CVRM were developed, but a clear clinical benefit is
absent. Some features of CDSS seem more promising
than others. However, the variability in approaches of
CDSS and heterogeneity of the results limit stronger
conclusions.
Due to differences in technical basis, content and com-
parison group, comparability of the studies included in
this review is limited. CDSS vary greatly in technical
approaches, as well as to how and to which extent they
support the physician. In addition, or as a result, there was
large heterogeneity in the results of the studies, such
that definite conclusions cannot be drawn from the
pooling of findings. Moreover, the usual care group
was ill defined such that it was impossible to under-
stand what care was delivered as standard. Visual in-
spection of funnel plots investigating the relationship
between effect and sample size does not show a distinct
publication bias (Additional file 3). But it is still possible
that positive results on CDSS are more likely to get pub-
lished. These aspects limit strong recommendations on
success factors in use of CDSS. Also, our analyses were
restricted by what was reported: some studies reported
raw means, prevalence or odds ratios, others reported
adjusted and/ or imputed effect measures [72, 76, 78, 84].
We were unable to incorporate these differences into our
analyses. An easy, but major step forward would be to
apply the existing guidelines for reporting trial results
using drug or devices in the publications and registration
in national or international trial registries.
Although very relevant in CVRM, effects on lifestyle
factors such as smoking and physical inactivity were out-
side the scope of this review. CDSS focus on guideline
adherent management measured by change in pharma-
cological treatment and risk factor profiles without regis-
tering meta-information on the decisions: how did the
CDSS affect counselling by the physician and the shared
decision making process? Helping the physician remem-
ber to address smoking can be achieved by CDSS, but
hów to address this has proven to be an important factor
in the uptake [92]. Lifestyle interventions in particular
need a more personal approach that is directed towards
coaching and long-term engagement, rather than inci-
dental support of guideline adherent management (the
goal of CDSS). Current literature is very positive about
Table 3 Study characteristics for studies on guideline adherence
Author Superiority/ Non-
inferiority
Inclusion period Follow up Guideline adhered Country Type of practice
Goud et.al,
2009 [87]
Superiority Jan 2005 - Dec 2005 12 months Cardiac
rehabilitation
The
Netherlands
Rehabilitation
center
Holbrook et.al,
2011 [88]
NR April 2003–June 2005 12 months NR Canada PCP
Mazzaglia et.al,
2016 [89]
Superiority NR 12 months ESC Italy PCP
Schnipper et.al,
2010 [90]
NR March 2007 - Aug 2007 30 days NR USA PCP
Sequist et.al,
2005 [91]
NR Oct 2002 – April 2003 6 months ADA/AHA USA PCP
NR not reported, RCT randomized controlled trial, PCP primary care practice, USA United States of America, L low risk of bias, U unknown risk of bias, H high risk of
bias, ESC European Society of Cardiology, AHA American Heart Association, ADA American Diabetes Association
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such smoking cessation interventions: there is consistent
evidence that web-based and mHealth smoking cessation
interventions may increase abstinence moderately [92].
Though the results are conflicting and strength of
conclusions is limited, the findings from this study can
perhaps be used to give direction to future develop-
ments. More evidence is needed on long-term evalua-
tions including assessment of the effect on treatment
adherence and vascular event rate [93]. This could the
also include other relevant cardiovascular risks such as
anti-coagulation therapy for patients with atrial fibril-
lation to prevent stroke, cardio protective medicine in
heart failure patients to prevent death or cardiac func-
tion replacement therapy, and fluid balance in patients
witch chronic kidney disease to prevent renal replace-
ment therapy. The paucity of good quality studies, with
sufficient sample size and follow up, on clinical out-
comes hinders interpretation and restricts transposing
these results into clinical practice. This again emphasizes
that guidance for generating relevant evidence needs to be
followed and taken up as requirement for funding and
publication of novel developments [94]. In designing a
study investigating the effect of CDSS, the CDSS’s life cycle
should be taken into account including the type of device,
the intended use and users, and working mechanism. The
device should be investigated in its natural habitat: ap-
plied to the same target individuals and in the same set-
ting as in usual care. The complex interplay between
device performance, user skills and learning curves has
to be incorporated methodologically [95]. The regula-
tory environment, including guidance on scientific
evaluation, regulations and legislation and privacy
issues needs to evolve together with this emerging field
of health technology.
CDSS in principle enable the physician to integrate
evidence and patient information into tailored strategies
for daily practice and increase guideline adherence [6, 26].
In this review, it seems that the technical basis, prompting
and the type of information provided influence the effect
of the CDSS on cardiovascular risk factor improvement.
Also, patient involvement in the CDSS process seems to
increase the effects. Roumie et al. added patient education
in a third study arm: 59.5% of the patients in this group
were on target regarding their blood pressure (compared
to usual care: RR 1.31 (95%CI 1.06; 1.62)). This significant
improvement could be driven by increased patient
empowerment. Patient empowerment can be defined
as a personal disposition (patient’s control over medical
strategies) and as a relational concept (collaborative
patient-doctor relation) and has been shown to signifi-
cantly increase the compliance to therapy [96–98]. The
Lancet Commission of Hypertension also suggests patient
empowerment as one of the strategies to address the
global burden of hypertension in the future [99].
Conclusion
In conclusion, we did not find a clear clinical benefit from
CDSS in cardiovascular risk factor levels and target attain-
ment. Some features of CDSS seem more promising than
others. However, the variability in CDSS characteristics
and heterogeneity of the results – emphasizing the imma-
turity of this research area - limit stronger conclusions.
Clinical relevance of CDSS in CVRM might additionally
be sought in the improvement of shared decision making
and patient empowerment.
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